439 related articles for article (PubMed ID: 7585581)
21. N-acetylation of the heterocyclic amine batracylin by human liver.
Stevens GJ; Payton M; Sim E; McQueen CA
Drug Metab Dispos; 1999 Sep; 27(9):966-71. PubMed ID: 10460792
[TBL] [Abstract][Full Text] [Related]
22. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon. Identity with the hepatic acetylation polymorphism.
Ogolla F; Ferguson RJ; Kirlin WG; Trinidad A; Andrews AF; Mpezo M; Hein DW
Drug Metab Dispos; 1990; 18(5):680-5. PubMed ID: 1981720
[TBL] [Abstract][Full Text] [Related]
23. N-Acetylation of p-aminobenzoic acid and p-phenylenediamine in primary porcine urinary bladder epithelial cells and in the human urothelial cell line 5637.
Föllmann W; Blaszkewicz M; Behm C; Degen GH; Golka K
J Toxicol Environ Health A; 2012; 75(19-20):1206-15. PubMed ID: 22994574
[TBL] [Abstract][Full Text] [Related]
24. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
[TBL] [Abstract][Full Text] [Related]
25. Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice.
Sugamori KS; Brenneman D; Grant DM
Drug Metab Dispos; 2011 May; 39(5):882-90. PubMed ID: 21317369
[TBL] [Abstract][Full Text] [Related]
26. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
27. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
28. Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: identity with polymorphic N-hydroxyarylamine-O-acetyltransferase.
Trinidad A; Hein DW; Rustan TD; Ferguson RJ; Miller LS; Bucher KD; Kirlin WG; Ogolla F; Andrews AF
Cancer Res; 1990 Dec; 50(24):7942-9. PubMed ID: 2253236
[TBL] [Abstract][Full Text] [Related]
29. N-Acetyltransferase and sulfotransferase activity in human prostate: potential for carcinogen activation.
Al-Buheissi SZ; Patel HR; Meinl W; Hewer A; Bryan RL; Glatt H; Miller RA; Phillips DH
Pharmacogenet Genomics; 2006 Jun; 16(6):391-9. PubMed ID: 16708048
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
31. Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.
Kadlubar FF; Dooley KL; Teitel CH; Roberts DW; Benson RW; Butler MA; Bailey JR; Young JF; Skipper PW; Tannenbaum SR
Cancer Res; 1991 Aug; 51(16):4371-7. PubMed ID: 1868460
[TBL] [Abstract][Full Text] [Related]
32. Arylamine N-acetyltransferase activities in human breast cancer tissues.
Geylan YS; Dizbay S; Güray T
Neoplasma; 2001; 48(2):108-11. PubMed ID: 11478689
[TBL] [Abstract][Full Text] [Related]
33. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes.
Cribb AE; Grant DM; Miller MA; Spielberg SP
J Pharmacol Exp Ther; 1991 Dec; 259(3):1241-6. PubMed ID: 1762071
[TBL] [Abstract][Full Text] [Related]
34. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
Cascorbi I; Roots I; Brockmöller J
Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
Hein DW
Mutat Res; 2002 Sep; 506-507():65-77. PubMed ID: 12351146
[TBL] [Abstract][Full Text] [Related]
36. 2-Aminofluorene-DNA adduct levels in tumor-target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus.
Feng Y; Jiang W; Hein DW
Toxicol Appl Pharmacol; 1996 Nov; 141(1):248-55. PubMed ID: 8917697
[TBL] [Abstract][Full Text] [Related]
37. Human N-acetylation of benzidine: role of NAT1 and NAT2.
Zenser TV; Lakshmi VM; Rustan TD; Doll MA; Deitz AC; Davis BB; Hein DW
Cancer Res; 1996 Sep; 56(17):3941-7. PubMed ID: 8752161
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the involvement of human N-acetyltransferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system.
Oda Y
Mutat Res; 2004 Oct; 554(1-2):399-406. PubMed ID: 15450435
[TBL] [Abstract][Full Text] [Related]
39. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
40. In vitro bioactivation of N-hydroxy-2-amino-alpha-carboline.
King RS; Teitel CH; Kadlubar FF
Carcinogenesis; 2000 Jul; 21(7):1347-54. PubMed ID: 10874013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
